Clinical Trial Update: Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of AL-53817 and AL-78843 ophthalmic solutions for allergic conjunctivitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• AL-53817 ophthalmic solution
• AL-78843 ophthalmic solution

Snippet

Sponsor: Alcon Research | Conditions: Allergic Conjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2015-08-06